Harvard Bioscience, Inc.
- Jurisdiction
United States - LEI
549300VLGB1D47GGC642 - ISIN
US4169061052 (HBIO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€75.70M - Gross margin
55.6% - EBIT
-€36.47M - EBIT margin
-48.2% - Net income
-€48.96M - Net margin
-64.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
| N/A | N/A | |
| N/A | N/A |
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 7, 2024 (Q1 2024)